The Birth Weight Lowering C-Alele of rs900400 Near LEKR1 and CCNL1 Associates with Elevated Insulin Release following an Oral Glucose Challenge

Ehm A. Andersson1, Marie N. Harder1*, Kasper Pilgaard2, Charlotte Pisinger2, Alena Stančáková4, Johanna Kuusisto4, Niels Grarup1, Kristine Færch2, Pernille Poulsen2, Daniel R. Witte2, Torben Jørgensen3,5, Allan Vaag2,6, Markku Laakso7, Oluf Pedersen1,7,8,9, Torben Hansen1,10

1 Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 2 Steno Diabetes Center, Gentofte, Denmark, 3 Research Centre for Prevention and Health, Gluşturup University Hospital, Gluşturup, Denmark, 4 Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 5 Department of Public Health, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark, 6 Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark, 7 Institute of Biomedical Science, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 8 Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark, 9 Hagedorn Research Institute, Gentofte, Denmark, 10 Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Abstract

Background and Aim: The first genome-wide association study on birth weight was recently published and the most significant associated birth weight lowering variant was the rs900400 C-allele located near LEKR1 and CCNL1. We aimed to replicate the association with birth weight in the Danish Inter99 study and furthermore to evaluate associations between rs900400 and indices of insulin secretion and insulin sensitivity obtained by oral glucose tolerance tests in adults from the Danish Inter99 study and the Finnish, Metabolic Syndrome in Men (METSIM) sample.

Methods: For 4,744 of 6,784 Inter99 participants, midwife journals were traced through the Danish State Archives and association of rs900400 with birth weight was examined. Associations between rs900400 and fasting serum insulin, fasting plasma glucose, insulinogenic index, homeostasis model assessment of insulin resistance (HOMA-IR) and disposition index were studied in 5,484 Danish and 6,915 Finnish non-diabetic individuals and combined in meta-analyses.

Results: The C-allele of rs900400 was associated with a 22.1 g lower birth weight (β = −41.3, 3.0, P = 0.024) per allele. Moreover, in combined analyses of the Danish Inter99 study and the Finnish METSIM study we found that the birth weight lowering allele was associated with increased insulin release measured by the insulinogenic index (β = 2.25% [0.59; 3.91], P = 0.008) and with an increased disposition index (β = 1.76% [0.04; 3.49], P = 0.05).

Conclusion: The birth weight lowering effect of the C-allele of rs900400 located near LEKR1 and CCNL1 was replicated in the Danish population. Furthermore the C-allele was associated with increased insulin response following oral glucose stimulation in a meta-analysis based on Danish and Finnish non-diabetic individuals.

Citation: Andersson EA, Harder MN, Pilgaard K, Pisinger C, Stančáková A, et al. (2011) The Birth Weight Lowering C-Alele of rs900400 Near LEKR1 and CCNL1 Associates with Elevated Insulin Release following an Oral Glucose Challenge. PLoS ONE 6(11): e27096. doi:10.1371/journal.pone.0027096

Editor: Michael Nicholas Weedon, Peninsula College of Medicine and Dentistry-University of Exeter, United Kingdom

Received: July 19, 2011; Accepted: October 10, 2011; Published: November 4, 2011

Copyright: © 2011 Andersson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by grants from the Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LuCAMP). The Inter99 was initiated by T. Jørgensen (principal investigator), K. Borck-Johnsen (co-principal investigator), H. Ibsen and T. F. Thomsen. The Steering Committee comprises the former two and C. Pisinger. The study was financially supported by research grants from the Danish Strategic Research Council, Hagedorn Research Institute, the Novo Nordisk Foundation Center for Basic Metabolic Research, the PhD School of Molecular Metabolism University of Southern Denmark and the Copenhagen Graduate School of Health Sciences. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and have the following conflicts; KF and DRW are employed by Steno Diabetes Center A/S, a research hospital working in the Danish National Health Service and owned by Novo Nordisk A/S and have employee shares in Novo Nordisk A/S. OP is employed by Hagedorn Research Institute, which is a basic research facility of Novo Nordisk and have employee shares in Novo Nordisk. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: marie.harder@sund.ku.dk

Introduction

Birth weight is a crude measure of the entire period of pre-natal growth. It is a complex trait influenced by multiple intrauterine factors as well as the genetic disposition of both the fetus and the mother. It is well known that low birth weight is associated with adult-onset metabolic diseases including type 2 diabetes (T2D) [1,2] and it has been hypothesized that this link is due to foetal growth restriction being detrimental for the natural organ development [3]. Besides, recent data provided proof-of-concept for the idea that the relationship between low birth weight and risk of T2D to some extent may be explained by common genetic disposition to both traits (the fetal insulin hypothesis) [4]. This hypothesis is based on insulin being an important fetal growth
factor, and thus genetic variation impairing insulin secretion or action may result in both reduced fetal growth and risk of T2D. Thus, lower birth weight was found among carriers of T2D risk alleles in or near HHEX-IDE, CDKAL1 and ADCY5 [5,6,7,8,9], however only the latter was confirmed at genome-wide significance. Risk alleles in HHEX-IDE and CDKAL1 confer increased risk of T2D due to lower insulin secretion [10,11] and the birth weight lowering effect of these two alleles suggests that insulin secretion is diminished already in pre-natal life. This may as well be the case for the ADCY5 risk allele, but the exact mechanism by which this variant predisposes to both low birth weight and T2D is yet to be determined [12]. However, several T2D risk alleles affecting adult insulin secretion have not been found to have an effect on birth weight. Variants in the FTO and TCF7L2 loci have been tested in large cohorts [13,14], but it cannot be excluded that for other variants the lack of association with birth weight might be due to missing power.

The first genome-wide association (GWA) study on birth weight demonstrated that rs983204 located in ADCY5 and rs900400 located near LEKRE and CCNL1 were associated with a decrease in birth weight by 0.063 and 0.086 z-score units per allele, respectively [5].

By investigating published GWA-databases from the GIANT and MAGIC consortia the authors found that, while the ADCY5 locus was related to T2D, rs900400 was not associated with either T2D, height, BMI, or fasting glycemic traits [5]. So far, genetic variants in or near LEKRE and CCNL1 have not been reported to be associated with adult metabolic phenotypes. Due to limited knowledge about this novel signal, we aimed to confirm the association between rs900400 and birth weight in the Danish population and furthermore to evaluate associations between rs900400 and five indices of insulin release and insulin sensitivity obtained from an oral glucose tolerance test in adults of the Danish Inter99 population and the Finnish Metabolic Syndrome in Men (METSIM) study as well as in combined analyses.

Materials and Methods

Study population

**Inter99.** Ethics statement: All participants gave written informed consent and the protocol was in accordance with the Helsinki Declaration, and approved by Copenhagen County ethic committee (ClinicalTrials.gov NCT00289257).

Individuals examined in the present study were from the Danish Inter99 study, which at baseline comprised 6,784 individuals living in the region of Copenhagen. The Inter99 study is a population-based, randomised non-pharmacological intervention study of prevention of ischemic heart disease conducted at the Research Centre for Prevention and Health in Glostrup, Denmark (www. inter99.dk) [15,16]. For 4,744 participants, midwife journals were traced through the Danish State Archives. These journals contained information on mother’s age, parity and marital status as well as birth weight, length at birth and prematurity of the newborn [17]. Ponderal index was calculated as birth weight (kg) / birth length (cm)$^2$. Birth weight characteristics of participants included in the study can be seen in Table 1. Information about maternal diabetes status (yes/no/unknown) was obtained by a questionnaire during the baseline visit in 1999–2001. The age of onset of maternal diabetes was not registered. Term birth was defined by a gestational week between 37 and 41. Preterm singleton deliveries (n = 446) and individuals born from multiple pregnancies (n = 83) were excluded. The final number of individuals included in the analyses of birth weight was 4,210.

| Table 1. Birth weight characteristics of participants from the Inter99 study and characteristics of non-diabetic participants from the Inter99 study and from the METSIM study. |
|---|---|---|---|
| Inter99 | N | Inter99 | N | METSIM |
| Years of birth | 1939–1970 | 4210 | 3488±450 |  |  |
| Birth weight (g) | 4197 | 52±2 | 6915 | 57.1±7.0 |  |  |
| Ponderal index | 4197 | 24.8±2.3 | 6915 | 57.1±7.0 |  |  |
| Body mass index (kg/m$^2$) | 5484 | 46.0±7.9 | 6915 | 57.1±7.0 |  |  |
| Body mass index (kg/m$^2$) | 5483 | 26.0±4.4 | 6912 | 26.8±3.8 |  |  |
| Fasting insulin (pmol/l) | 5292 | 40.6±26.1 | 6911 | 49.1±34.0 |  |  |
| Fasting plasma glucose (mmol/l) | 5479 | 5.5±0.5 | 6915 | 5.7±0.5 |  |  |
| HOMA-IR (mmol/l*pmol/l) | 5290 | 1.7±1.1 | 6911 | 2.1±1.5 |  |  |
| Insulinogenic index (pmol/l / nmol/l) | 5040 | 29.8±19.6 | 6876 | 39.9±30.1 |  |  |
| Disposition index | 5040 | 22.6±16.8 | 6876 | 22.6±16.0 |  |  |

Data are mean ± standard deviation or median (interquartile range). doi:10.1371/journal.pone.0027096.t001

Biochemical measures

**Inter99.** Blood samples were drawn after an overnight fast followed by an OGTT. Plasma glucose was analyzed by a glucose oxidase method (Granutest; Merck, Darmstadt, Germany). Serum insulin (excluding des-31,32) and intact proinsulin was measured using the AutoDELFIA insulin kit (Perkin-Elmer, Wallac, Turku, Finland).

**METSIM.** Blood samples were drawn after 12 h of fasting followed by an OGTT. Plasma glucose was measured from plasma (FC-mixture: NaF/ Na-Citrate/ EDTA-Na2) by Enzymatic photometric test, Glucose hexokinase. Reagent: Konelab System.
Reagents, Glucose (HK), Thermo Fisher Scientific, Vantaa, Finland. Instrumentation: Konelab 20XTi Clinical Chemistry Analyzer, Thermo Fisher Scientific, Vantaa, Finland. Insulin was measured in mU/l units (converted to pmol/l multiplying by 6) from plasma (EDTA) by Immunoassay, luminometric measurement. Reagent: ADVIA Centaur Insulin IRI, no 02220141, Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA. Instrumentation: Siemens ADVIA Centaur®, Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA.

Indices of insulin release and insulin sensitivity for both study samples. Oral glucose-stimulated insulin release was reported as the insulinogenic index. The insulinogenic index was calculated as serum insulin at 30 minutes [pmol/l]-fasting serum insulin [pmol/l] / plasma glucose at 30 minutes [mmol/l]. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as (fasting plasma glucose [mmol/l] * fasting serum insulin [pmol/l]) / 22.5 in the METSIM cohort. In order to construct an OGTT-based disposition index, we divided insulinogenic index with the reciprocal of HOMA-IR (Insulinogenic index/HOMA-IR). Clinical characteristics of the Inter99 and METSIM individuals are shown in Table 1.

Genotyping
Inter99. Genotyping was performed using KASPar® genotyping (KBioScience, Hoddesdon) with a success rate of 98.3% and an error rate of 0% in 454 duplicate samples. There was a slight deviation from Hardy Weinberg equilibrium ($P=0.011$).

METSIM. Genotyping was performed using the Applied Biosystems TaqMan Allelic Discrimination Assay with a success rate of 98.1% and an error rate of 0% in 4.5% duplicate samples. The genotype distribution was consistent with Hardy Weinberg equilibrium ($P=1.0$).

Statistical analysis
Inter99. All statistical analyses were performed using RGui version 2.8.1 (available at http://www.r-project.org). The associations of rs900400 with birth weight, length at birth and ponderal index in the Inter99 population were calculated using linear regression models adjusted for sex, maternal diabetes (yes vs. no/NA) and parity (0, 1, 2, 3 or ≥4). Z-scores were calculated as [value-mean]/standard deviation (based on the mean and SD birth weight in the included Inter99 sample).

METSIM. Statistical analyses were performed using SPSS version 17 (SPSS, Chicago, IL). Associations with quantitative variables during an OGTT were performed as described below.

Both studies. Associations of rs900400 with indices of insulin release and insulin sensitivity were performed by linear regression models adjusted for age or for age and BMI (the analyses were also adjusted for sex in the Inter99 sample). Effect sizes are given as actual values or percentage (%) if the trait was natural logarithmically (ln) transformed. Only additive genetic models were considered assuming a constant change per risk allele and a $P$-value <0.05 was considered significant.

Fixed effect meta-analyses (up to n = 12,394) were performed using effect size estimates and standard errors (SE) derived from linear regression analyses from the Inter99 (adjusted for age and sex) and the METSIM (adjusted for age) populations. The weight of the two studies in the meta-analyses was estimated using inverse variance assuming fixed effects. Heterogeneity was measured by $Q$-statistics.

Statistical power was estimated using 1000 simulations. We used the empirical variance of the observed traits in the Danish Inter99 cohort to simulate phenotypes from a normal distribution, so that variance across genotypes is drawn from the estimated variance.

In the combined analyses, we have estimated the effect sizes that we have more than 90% statistical power to detect ($P<0.05$) assuming a minor allele frequency of 40% resembling the HapMap-CEU frequency of rs900400 (Table S1).

Results
In 4,210 individuals from the Danish Inter99 population the C-allele of rs900400 near LEKRI and CCNL1 was associated with 22.1 g lower birth weight per allele (95% CI –41.3;–3.0, $P=0.024$). A trend towards a lower ponderal index was also observed ($β=–0.08 [–0.18;0.01], P=0.094$) for carriers of the C-allele, whereas length at birth was not associated with rs900400 ($P=0.230$) (Table 2).

In the Inter99 study, we found that the birth weight lowering C-allele was associated with increased insulin release as estimated by the insulinogenic index ($β=3.3%\,[1.0;5.6], P=0.005$) as well as increased disposition index ($β=3.6%\,[1.0;6.2], P=0.007$) (Table 3). Moreover, we found a lower fasting plasma glucose level ($–0.02\,\text{mmol/l}\,[–0.04;–0.002], P=0.021$) for carriers of the birth weight lowering allele in the Inter99 cohort. These observations, except the findings for fasting plasma glucose, were also observed in the subgroup of individuals with normal glucose tolerance in Inter99 (data not shown). The C-allele of rs900400 was not significantly associated with any of the five traits in the METSIM population (table 3). However, the directions of the associations with insulinogenic index and disposition index were similar to what was observed in the Inter99 sample although the effect size estimates were considerably smaller in the METSIM population. Additional adjustment for BMI in all analyses did not

Table 2. Associations between rs900400 near LEKRI and CCNL1 and birth weight, birth length and ponderal index in the Danish Inter99 sample.

|            | TT   | TC   | CC   | Effect | Effect z-score | P    |
|------------|------|------|------|--------|----------------|------|
| N          | 1332 | 1875 | 722  |        |                |      |
| (Men/Women)| (640/692) | (893/982) | (326/396) |        |                |      |
| Birth weight (g) | 3493±451 | 3503±446 | 3435±439 | –22.1 [–41.3;–3.0] | –0.05 [–0.09;–0.01] | 0.024 |
| Birth length (cm) | 52±2 | 52±2 | 52±2 | –0.05 [–0.13;0.03] | –0.01 [–0.07;0.02] | 0.23 |
| Ponderal index (kg/m³) | 24.8±2.3 | 24.8±2.3 | 24.6±2.2 | –0.08 [–0.18;0.01] | –0.04 [–0.08;0.01] | 0.094 |

Effects and P-values are adjusted for sex, maternal diabetes and parity assuming an additive model of inheritance. Ponderal index was calculated as birth weight (kg)/birth length (m)².

doi:10.1371/journal.pone.0027096.t002
change the level of significance. Fixed effect meta-analyses of data from the Inter99 and METSIM studies were performed for all five metabolic traits (fasting serum insulin, fasting plasma glucose, insulinogenic index, HOMA-IR and disposition index) including up to 12,394 individuals. In combined meta-analyses the C-allele of rs900400 was associated with increased insulin response to an oral glucose load estimated by the insulinogenic index ($\beta = 2.25\% [0.59; 3.91]$, $P = 0.008$, figure 1 and table 4) and with an increased

Table 3. Associations between rs900400 near LEKR1 and CCNL1 and quantitative metabolic traits during an oral glucose tolerance test in 5,484 non-diabetic participants of the Inter99 study and 6,915 non-diabetic men from the METSIM study.

|               | TT       | TC       | CC       | Effect [95% CI] | P   |
|---------------|----------|----------|----------|-----------------|-----|
| Inter99 N (Men/Women) | 1908(926/982) | 2584(1297/1287) | 992(463/529) |                |     |
| Age (years)   | 46.8 ± 8 | 46.8 ± 8 | 45.8 ± 8 |                |     |
| Fasting serum insulin (pmol/l) | 40.91 ± 26.05 | 40.09 ± 26.16 | 41.05 ± 26.09 | -0.3% [-2.4; 1.9] | 0.81 |
| Fasting plasma glucose (mmol/l) | 5.47 ± 0.51 | 5.46 ± 0.51 | 5.41 ± 0.52 | -0.02 mmol/l [-0.04; 0.0] | 0.021 |
| HOMA-IR (µU/l * mmol/l) | 1.68 ± 1.13 | 1.65 ± 1.14 | 1.67 ± 1.12 | -0.6% [-2.9; 1.7] | 0.62 |
| Insulinogenic index (pmol/l / mmol/l) | 29.07 ± 18.26 | 29.51 ± 19.36 | 31.69 ± 22.14 | 3.3% [1.0; 5.6] | 0.005 |
| Disposition index (Insulinogenic index / HOMA-IR) | 21.91 ± 15.92 | 22.5 ± 16.32 | 23.89 ± 19.23 | 3.6% [1.0; 6.2] | 0.007 |

METSIM

|               | TT       | TC       | CC       | Effect [95% CI] | P   |
|---------------|----------|----------|----------|-----------------|-----|
| N             | 3331     | 2934     | 647      |                |     |
| Age (years)   | 57.0 ± 6.9 | 57.1 ± 7.0 | 57.5 ± 7.0 |                |     |
| Fasting plasma insulin (pmol/l) | 48.88 ± 33.51 | 49.19 ± 34.44 | 50.04 ± 34.61 | 0.9% [-1.2; 3.0] | 0.419 |
| Fasting plasma glucose (mmol/l) | 5.70 ± 0.48 | 5.71 ± 0.49 | 5.70 ± 0.47 | 0.00 mmol/l [-0.02; 0.02] | 0.982 |
| HOMA-IR (µU/l *mmol/l) | 2.10 ± 1.53 | 2.11 ± 1.55 | 2.14 ± 1.52 | 0.9% [-1.4; 3.1] | 0.445 |
| Insulinogenic index (pmol/l / mmol/l) | 39.55 ± 29.53 | 40.03 ± 30.53 | 40.92 ± 30.93 | 1.2% [-1; 2.3] | 0.340 |
| Disposition index (Insulinogenic index / HOMA-IR) | 22.56 ± 16.25 | 22.70 ± 15.81 | 22.32 ± 15.34 | 0.2% [-2.1; 2.4] | 0.890 |

Data are mean ± SD and are stratified according to genotype of rs900400. Effects are given as actual values (plasma glucose) or percentage (%) (all other traits) since these traits are logarithmically transformed. Effects and p-values are adjusted for age (and sex in Inter99) assuming an additive model of inheritance.

doi:10.1371/journal.pone.0027096.t003

Figure 1. Meta-analysis of rs900400 and insulinogenic index including 11,916 individuals from the Inter99 and METSIM study. Effect size estimates and standard errors are combined in a meta-analysis using the inverse variance method. The black diamond represents the combined change in insulinogenic index per C-allele. Effect size estimate ($\beta$) and $P$-value are presented for the combined analysis with 95% confidence interval in square brackets.

doi:10.1371/journal.pone.0027096.g001
disposition index in C-allele carriers \( (\beta = 1.76\% \ [0.04; 3.49], P = 0.05) \)
(table 4). No other traits were associated with rs900400 in the meta-analyses (table 4). No heterogeneity was observed in any of the meta-analyses \((P > 0.05)\).

### Discussion

We confirm the association of rs900400 C-allele near LEKR1 and CCNL1 with lower birth weight in the Danish Inter99 study sample. The same allele was found by Freathy et al. to be associated with a lower ponderal index in 21,515 European individuals \([5]\). We also observe a trend towards a lower ponderal index, although this trait does not reach statistical significance in our cohort.

Our confidence interval is just overlapping with the estimated effect size reported by Freathy et al., indicating that statistically the effect sizes are similar in the two cohorts. However, the effect size estimates of birth weight and ponderal index in the present study are slightly lower than the combined effects reported by Freathy et al. \([5]\). This could be explained by general population differences and slight deviations in linkage equilibrium among the populations, assuming that this polymorphism is not the causative variant. Moreover, we were not able to adjust for gestational age also impeding the accuracy of birth weight as a measure of growth conditions. However, in the GWA meta-analysis three studies without information about gestational age did not introduce heterogeneity in the overall analyses suggesting that this variant is not strongly associated with gestational age \([5]\).

Surprisingly, in meta-analyses based on the Danish Inter99 and Finnish METSIM studies we found an increased oral glucose stimulated insulin release measured by the insulinogenic index and the disposition index in carriers of the birth weight lowering C-allele. The disposition index could be considered as an estimate of the level of insulin sensitivity. If these data are upheld in larger study settings, the disposition index in carriers of the birth weight lowering C-allele \((P = 0.05)\).

### Supporting Information

#### Table S1

| Combined meta-analyses       | N      | Effect [95% CI] | P     | P (heterogeneity) |
|-----------------------------|--------|----------------|-------|------------------|
| Fasting insulin (pmol/l)    | 12,203 | 0.3% [–1.22; 1.82] | 0.70  | 0.44             |
| Fasting plasma glucose (mmol/l) | 12,394 | –0.0088 mmol/l [–0.02; 0.004] | 0.19  | 0.13             |
| HOMA-IR (\(\mu U/l \times \text{ mmol/l}\)) | 12,201 | 0.20% [–1.37; 1.77] | 0.81  | 0.35             |
| Insulinogenic index (pmol/l / mmol/l) | 11,916 | 2.25% [0.59; 3.91] | 0.008 | 0.22             |
| Disposition index (insulinogenic index / HOMA-IR) | 11,916 | 1.76% [0.04; 3.49] | 0.045 | 0.055            |

The effect size estimates represents the combined change of the different traits per C-allele. P-values are presented for the combined analysis. P-values for heterogeneity are also presented.

doi:10.1371/journal.pone.0027096.t004

In conclusion, we confirm the association with lower birth weight in carriers of the birth weight lowering C-allele. The validity of the present findings needs to be tested in future studies.

### References

1. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A (2007) Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 165: 849–857.

2. Pilgaard K, Faerch K, Carstensen B, Poulsen P, Pisinger C, et al. (2010) Low birthweight and premature birth are both associated with type 2 diabetes in a random sample of middle-aged Danes. Diabetologia 53: 2526–2530.
3. Hales CN, Barker DJ (2001) The thrifty phenotype hypothesis. Br Med Bull 60: 5–20.
4. Hattersley AT, Tooke JE (1999) The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 353: 1709–1792.
5. Freathy RM, Mook-Kanamori DO, Sovio U, Prokopenko I, Timpon NJ, et al. Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet.
6. Andersson EA, Pilgaard K, Pisinger C, Harder MN, Grarup N, et al. Type 2 diabetes risk alleles near ADCY5, CDKAL1 and HHEX-IDE are associated with reduced birthweight. Diabetologia 53: 1908–1916.
7. Freathy RM, Bennett AJ, Ring SM, Shield B, Groves CJ, et al. (2009) Type 2 diabetes risk alleles are associated with reduced size at birth. Diabetes 58: 1428–1433.
8. Pulizzi N, Lyssenko V, Jonsson A, Omdard M, Liaw C, et al. (2009) Interaction between prenatal growth and high-risk genotypes in the development of type 2 diabetes. Diabetologia 52: 825–829.
9. Zhao J, Li M, Bradford JP, Wang K, Zhang H, et al. (2009) Examination of type 2 diabetes loci implicates CDKAL1 as a birth weight gene. Diabetes 58: 2414–2418.
10. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, et al. (2007) Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56: 3105–3111.
11. Steinhorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, et al. (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39: 770–775.
12. Dupuis J, Langenberg G, Prokopenko I, Saxena R, Soranzo N, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105–116.
13. Freathy RM, Weedon MN, Bennett A, Hypponen E, Rotles CL, et al. (2007) Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. American journal of human genetics 80: 1150–1161.
14. Kilpelainen TO, den Hoed M, Ong KK, Grontved A, Brage S, et al. (2011) Obesity-susceptibility loci have a limited influence on birth weight: a meta-analysis of up to 28,219 individuals. The American journal of clinical nutrition 93: 851–860.
15. Jorgensen T, Borgh-Johnsen K, Thomsen TF, Ibsen H, Grarup C, et al. (2003) A randomized non-pharmacological intervention study for prevention of ischemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10: 377–386.
16. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, et al. (2007) Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56: 3105–3111.
17. Who (1999) Part 1: Diagnosis and classification of Diabetes Mellitus. Tech. Rep. Ser., no.WHO/NCD/NCS99.2.
18. Dusatkova P, Pruhova S, Sumnik Z, Kolouskova S, Obermannova B, et al. (2011) HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. Journal of pediatric endocrinology & metabolism JPEM 24: 107–109.